Clinical Scorecard: Evaluating the Health Advantages, Financial Implications, and Economic Viability of Hepatitis C Elimination Initiatives in Correctional Facilities
At a Glance
Category
Detail
Condition
Hepatitis C Virus (HCV) Infection
Key Mechanisms
Direct-acting antiviral (DAA) treatments and jail-based interventions
Target Population
People who inject drugs, particularly those in correctional facilities
Care Setting
Jails and community health settings
Key Highlights
US aims to reduce new HCV infections by 90% and HCV-related deaths by 65% by 2030.
Injection drug use is the primary transmission route for HCV.
Jails have higher admission volumes and shorter detention periods, presenting unique intervention opportunities.
DAA treatments enhance the feasibility of jail-based HCV interventions.
Innovative strategies are needed to engage justice-involved individuals in HCV care.
Guideline-Based Recommendations
Diagnosis
HCV testing at jail entry with high coverage.
Management
Implement HCV navigation and treatment initiation in jail settings.
Monitoring & Follow-up
Continuity of care post-release through community navigation.
Risks
High loss to follow-up due to uncertain release dates and staff shortages.
Patient & Prescribing Data
Individuals who inject drugs, especially those in jails.
DAA treatments require 8 to 12 weeks of oral medication with high cure rates.
by Lin Zhu, Lora N. Magaldi, Indrani A. Wagh, Eliza R. Ennis, Marissa B. Reitsma, Danica E. Kuncio, Eman Addish, Sandy R. Varghese, Nathan W. Furukawa, Amanda A. Honeycutt, Yijie Chen, Benjamin P. Linas, Joshua A. Salomon
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
